Table of Contents
- Overview
- Symptoms
- Treatment
- Prevention
- Images
Cancer - ovaries
Treatment
Surgery is used to treat all stages of ovarian cancer. For earlier stage ovarian cancer, it may be the only treatment. Surgery involves:
- Removal of the uterus (total
hysterectomy ) - Removal of both ovaries and fallopian tubes (bilateral salpingo-oophorectomy)
- Partial or complete removal of the omentum, the fatty layer that covers and pads organs in the abdomen
- Examination, biopsy, or removal of the lymph nodes and other tissues in the pelvis and abdomen
Surgery performed by a specialist in female reproductive cancer has been shown to result in a higher success rate.
After surgery and chemotherapy, patients should have:
- A physical exam (including pelvic exam) every 2 - 4 months for the first 2 years, followed by every 6 months for 3 years, and then annually
- A
CA-125 blood test at each visit if the level was initially high - Your doctor may also order a computed tomography (
CT ) scan of your chest, abdomen, and pelvic area and a chest x-ray.
Support Groups
For additional information and resources, see
Expectations (prognosis)
Ovarian cancer is rarely diagnosed in its early stages. It is usually quite advanced by the time diagnosis is made
- About 3 out of 4 women with ovarian cancer survive 1 year after diagnosis.
- Nearly half of women live longer than 5 years after diagnosis.
- If diagnosis is made early in the disease and treatment is received before the cancer spreads outside the ovary, the 5-year survival rate is very high
Complications
- Spread of the cancer to other organs
- Loss of organ function
- Fluid in the abdomen (
ascites ) - Blockage of the intestines
Calling your health care provider
Call for an appointment with your health care provider if you are a woman over 40 years old who has not recently had a pelvic examination. Routine pelvic examinations are recommended for all women over 20 years old.
Call for an appointment with your provider if you have symptoms of ovarian cancer.
Images
Previous Section
Review Date: 12/28/2010
Reviewed By: Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program,
Massachusetts General Hospital. Also reviewed by David Zieve, MD,
MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org)
